Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1636 1637 1653 1682 1699
This examiner grants 50% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18035901 | METHODS AND MATERIALS FOR TREATING HEART FAILURE | Final Rejection | Mayo Foundation for Medical Education and Research |
| 18549951 | COMPOSITIONS AND METHODS FOR DOMINANT ANTIVIRAL THERAPY | Non-Final OA | Massachusetts Institute of Technology |
| 17785070 | PROGRAMMABLE DNA NUCLEASE-ASSOCIATED LIGASE AND METHODS OF USE THEREOF | Final Rejection | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 16772222 | CAS12B SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED DNA BASE EDITING | Final Rejection | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18568797 | METHODS AND COMPOSITIONS FOR MODULATING STING SIGNALING AND INNATE IMMUNE RESPONSES | Non-Final OA | The General Hospital Corporation |
| 18549252 | COMPOSITIONS AND METHODS FOR ASSESSING AND TREATING T CELL DYSFUNCTION | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 17831232 | INTEGRATED DRUG DISCOVERY PLATFORM FOR PROTEIN MISFOLDING DISORDERS ASSOCIATED WITH METABOLITE ACCUMULATION | Non-Final OA | Ramot at Tel-Aviv University Ltd. |
| 17802004 | G PROTEIN-COUPLED RECEPTOR 146 (GPR146) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | ALNYLAM PHARMACEUTICALS, INC. |
| 18724236 | LIPID-BASED FORMULATIONS FOR ADMINISTRATION OF RNA | Non-Final OA | BIONTECH SE |
| 18577107 | OLIGONUCLEOTIDES AND VIRAL UNTRANSLATED REGION (UTR) FOR INCREASING EXPRESSION OF TARGET GENES AND PROTEINS | Non-Final OA | Temple University - of the Commonwealth System of Higher Education |
| 17721765 | Compositions for Modulating C9ORF72 Expression | Final Rejection | Ionis Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy